Elucidating the Mechanism of 1,4,5,6,7,8‐Hexahydropyrido[4,3‐d]Pyrimidine‐Induced Inhibition of Glioma Growth Through miR‐873‐3p
Molecular Carcinogenesis · 2026-02 · 65 (2) · 167-185
DOI: 10.1002/mc.70061 ↗Abstract
ABSTRACT Glioblastoma (GBM) represents an exceedingly malignant and invasive type of brain tumor, known for its significant tendency to recur and its unfavorable clinical outcome. Despite significant advancements in research and therapeutic strategies, the survival rates for patients with GBM remain low. Synthesis of 1,4,5,6,7,8‐hexahydropyridine [4,3‐d] pyrimidine (PPM) has emerged as a promising avenue for the development of novel therapeutic agents with potent anti‐glioma efficacy and minimal toxicity. Although previous studies have demonstrated the ability of PPM to inhibit HepG2 cell proliferation and suppress liver cancer, its potential anti‐glioma effects and the underlying mechanisms remain largely unexplored. Using a comprehensive array of experimental approaches, this study was designed to elucidate both the therapeutic potential and underlying molecular mechanisms of PPM in GBM, including western blotting, flow cytometry, EdU assay, clone formation analysis, immunofluorescence, qRT‐PCR, wound healing assay, Transwell migration/invasion assay, and a dual‐luciferase reporter gene system. In vitro experiments demonstrated that PPM exhibited significant inhibitory effects on tumor cell proliferation, migration, and invasion. Furthermore, PPM treatment induced cell cycle arrest and promoted both apoptosis and autophagy, and its antitumor effects were mediated by the inhibition of autophagosome degradation. Mechanistically, PPM exerted its anti‐glioma effects through the upregulation of miR‐873‐3p, which subsequently inhibited the PI3K/AKT/mTOR signaling pathway. Through the integration of proteomic profiling and bioinformatics approaches, PTBP1 was identified as a putative downstream target gene regulated by miR‐873‐3p. Suppression of miR‐873‐3p upregulates PTBP1 expression, thereby facilitating the progression and development of glioma cells. These findings suggest that PPM is a promising therapeutic candidate for GBM treatment and offer novel insights into glioma therapy. The identification of the miR‐873‐3p/PTBP1 axis as a potential therapeutic target provides a new direction for future clinical applications and GBM treatment strategies.
EUVIMED